Arcutis Biotherapeutics, Inc. - Common Stock (ARQT)

Q3 2020 13F Holders as of 30 Sep 2020

Type / Class
Equity / Common Stock
Shares outstanding
120,138,422
Total 13F shares
34,766,158
Share change
+988,112
Total reported value
$1,018,651,387
Price per share
$29.30
Number of holders
62
Value change
+$28,894,471
Number of buys
40
Number of sells
14

Institutional Holders of Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) as of Q3 2020

As of 30 Sep 2020, Arcutis Biotherapeutics, Inc. - Common Stock (ARQT) was held by 62 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 34,766,158 shares. The largest 10 holders included FRAZIER MANAGEMENT LLC, FMR LLC, ORBIMED ADVISORS LLC, Bain Capital Life Sciences Investors, LLC, BlackRock Inc., RA CAPITAL MANAGEMENT, L.P., Vivo Capital, LLC, PRICE T ROWE ASSOCIATES INC /MD/, VANGUARD GROUP INC, and Omega Fund Management, LLC. This page lists 62 institutional shareholders reporting positions in this security for the Q3 2020 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.